Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979405718> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2979405718 abstract "Abstract Introduction: Development of antibodies (ab) against factor VIII (FVIII) is a serious complication of replacement therapy in patients with hemophilia A. In case of bleeding patients with FVIII ab are treated with agents that induce hemostasis independently of FVIII. Recombinant activated factor VIIa (rVIIa) shows clinical efficacy, but its effects on hemostatic system need still to be fully elucidated. Methods: In an open controlled study, we investigated thrombin generation (peak thrombin) and parameters of coagulation activation [D-Dimer, prothrombin fragment F1+2 (F1+2)] in 5 patients with hemophilia A and FVIII ab, and in 5 healthy age-matched controls before and after intravenous bolus infusion of rVIIa (90 μg/kg bodyweight NovoSeven®, NovoNordisk, Denmark) (in hemophiliacs only). All parameters were measured in plasma before and 0.5, 1, 2, 3, and 4 hours after rVIIa infusion by use of commercially available assays (Technothrombin®TGA, Technoclone, Austria; Asserachrom®D-Di, Diagnostica Stago, France; Enzygnost F1+2, Dade Behring, Germany). Results: At baseline, hemophilia A patients had markedly lower mean (min-max) peak thrombin levels than controls [0.12 (0.0–0.6) nM vs. 186.9 (116.0–254.4) nM]. Mean (min-max) F1+2 levels did not significantly differ between patients and controls [160.7 (89.8–331.3) pmol/l vs. 160.8 (104.4–242.3) pmol/l]. Notably, D-Dimer levels were significantly higher in hemophiliacs than controls [1087.5 (174.8–3882.4) ng/ml vs. 146.3 (87.2–289.8) ng/mL]. FVIIa levels reached a mean (min-max) maximum of 28 (24–32) U/ml after 0.5 hours in all patients. After infusion, a considerable increase in mean (min-max) peak thrombin levels to 40.7 (28.3–51.6) nM was seen. Time to maximum levels was 30 minutes in three patients and 60 minutes in two. For each of the five patients the peak thrombin level was substracted from the level of its matched control at the same time point. The mean of these differences was 168.7 nM (95% CI 82.6–254.8), which translates into 80.2% (95% CI 65.4% – 88.6%) lower peak thrombin levels in haemophiliacs with FVIII ab. F1+2 significantly increased in all patients [mean (min-max) maximum levels 292.5 (175.1–464.3) pmol/l]; time to maximum levels varied from 2 to 4 hours. D-Dimer levels remained almost unchanged in all patients. Conclusion: Patients with hemophilia A and FVIII ab have low in vitro thrombin generation and F1+2 levels. After rVIIa infusion, coagulation activation as measured by F1+2 levels is slightly increased, and thrombin generation capacity is restored by 20% compared to healthy controls. Measurement of peak thrombin could be useful to monitor procoagulant treatment of patients with hemophilia A and FVIII ab." @default.
- W2979405718 created "2019-10-18" @default.
- W2979405718 creator A5015899523 @default.
- W2979405718 creator A5029001758 @default.
- W2979405718 creator A5053093013 @default.
- W2979405718 creator A5060041875 @default.
- W2979405718 creator A5065148709 @default.
- W2979405718 creator A5071157720 @default.
- W2979405718 date "2007-11-16" @default.
- W2979405718 modified "2023-10-18" @default.
- W2979405718 title "Effects of Recombinant Factor VIIa (NovoSeven®) on Restoring Thrombin Generation in Patients with Hemophilia A and Antibodies to Factor VIII." @default.
- W2979405718 doi "https://doi.org/10.1182/blood.v110.11.1161.1161" @default.
- W2979405718 hasPublicationYear "2007" @default.
- W2979405718 type Work @default.
- W2979405718 sameAs 2979405718 @default.
- W2979405718 citedByCount "0" @default.
- W2979405718 crossrefType "journal-article" @default.
- W2979405718 hasAuthorship W2979405718A5015899523 @default.
- W2979405718 hasAuthorship W2979405718A5029001758 @default.
- W2979405718 hasAuthorship W2979405718A5053093013 @default.
- W2979405718 hasAuthorship W2979405718A5060041875 @default.
- W2979405718 hasAuthorship W2979405718A5065148709 @default.
- W2979405718 hasAuthorship W2979405718A5071157720 @default.
- W2979405718 hasConcept C104317684 @default.
- W2979405718 hasConcept C126322002 @default.
- W2979405718 hasConcept C141071460 @default.
- W2979405718 hasConcept C159654299 @default.
- W2979405718 hasConcept C185592680 @default.
- W2979405718 hasConcept C203014093 @default.
- W2979405718 hasConcept C2777232031 @default.
- W2979405718 hasConcept C2777292125 @default.
- W2979405718 hasConcept C2778382381 @default.
- W2979405718 hasConcept C2778385053 @default.
- W2979405718 hasConcept C2778589496 @default.
- W2979405718 hasConcept C2778961111 @default.
- W2979405718 hasConcept C2779519742 @default.
- W2979405718 hasConcept C2779936836 @default.
- W2979405718 hasConcept C40767141 @default.
- W2979405718 hasConcept C42219234 @default.
- W2979405718 hasConcept C55493867 @default.
- W2979405718 hasConcept C71924100 @default.
- W2979405718 hasConcept C89560881 @default.
- W2979405718 hasConcept C90924648 @default.
- W2979405718 hasConceptScore W2979405718C104317684 @default.
- W2979405718 hasConceptScore W2979405718C126322002 @default.
- W2979405718 hasConceptScore W2979405718C141071460 @default.
- W2979405718 hasConceptScore W2979405718C159654299 @default.
- W2979405718 hasConceptScore W2979405718C185592680 @default.
- W2979405718 hasConceptScore W2979405718C203014093 @default.
- W2979405718 hasConceptScore W2979405718C2777232031 @default.
- W2979405718 hasConceptScore W2979405718C2777292125 @default.
- W2979405718 hasConceptScore W2979405718C2778382381 @default.
- W2979405718 hasConceptScore W2979405718C2778385053 @default.
- W2979405718 hasConceptScore W2979405718C2778589496 @default.
- W2979405718 hasConceptScore W2979405718C2778961111 @default.
- W2979405718 hasConceptScore W2979405718C2779519742 @default.
- W2979405718 hasConceptScore W2979405718C2779936836 @default.
- W2979405718 hasConceptScore W2979405718C40767141 @default.
- W2979405718 hasConceptScore W2979405718C42219234 @default.
- W2979405718 hasConceptScore W2979405718C55493867 @default.
- W2979405718 hasConceptScore W2979405718C71924100 @default.
- W2979405718 hasConceptScore W2979405718C89560881 @default.
- W2979405718 hasConceptScore W2979405718C90924648 @default.
- W2979405718 hasLocation W29794057181 @default.
- W2979405718 hasOpenAccess W2979405718 @default.
- W2979405718 hasPrimaryLocation W29794057181 @default.
- W2979405718 hasRelatedWork W111093037 @default.
- W2979405718 hasRelatedWork W18576501 @default.
- W2979405718 hasRelatedWork W1897057798 @default.
- W2979405718 hasRelatedWork W1963828782 @default.
- W2979405718 hasRelatedWork W2023412739 @default.
- W2979405718 hasRelatedWork W2046564088 @default.
- W2979405718 hasRelatedWork W2066814928 @default.
- W2979405718 hasRelatedWork W2091908750 @default.
- W2979405718 hasRelatedWork W2170353634 @default.
- W2979405718 hasRelatedWork W2979405718 @default.
- W2979405718 isParatext "false" @default.
- W2979405718 isRetracted "false" @default.
- W2979405718 magId "2979405718" @default.
- W2979405718 workType "article" @default.